Global Genomics Group and Datavant Announce Strategic Partnership to Improve Design and Interpretation of Clinical Trials

Friday, January 5, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

- G3 and Datavant today announced the formation of a strategic partnership to improve the design and interpretation of clinical trials

SAN FRANCISCO and ATLANTA, Jan. 5, 2018 /PRNewswire/ -- Global Genomics Group ("G3"),

a precision-medicine-based biopharmaceutical company that leverages large-scale genomic and molecular profiling to develop life-changing diagnostics and therapeutics, and Datavant, a healthcare technology company that aggregates and structures healthcare data to generate actionable insights for clinical trial design and interpretation, today announced a strategic partnership to improve the design and interpretation of clinical trials.

Through this partnership, Datavant and G3 will work together to increase the odds of success and pace of drug development through data-driven approaches. The partners will use G3's proprietary platform and data from the G3LOBAL database, a panomic dataset characterizing disease networks and biomarkers in approximately 8,000 patients. The robust dataset includes whole-genome sequencing, whole-transcriptome sequencing, proteomics, lipodomics, lipoprotein proteomics, and quantitative precision imaging data. Together with Datavant's Clinical Trial Data Cloud, a longitudinal combination of real-world evidence and clinical trial data, and advanced analytics, the partners expect to create new models for developing trial enrollment criteria, endpoints, and contextualizing trial results.

"We are delighted to work with Datavant to improve pharmaceutical clinical trial design and interpretation. The traditional model of drug development and clinical trial programs is no longer sustainable, and we believe that the combination of biological Big Data, together with sophisticated analytical tools, such as artificial intelligence and machine learning, are essential to turning around the pharmaceutical industry and drug development. We see Datavant at a very important intersection of cutting-edge analytical sciences and life sciences and we are looking forward to working together," said Szilard Voros, Founder and CEO of G3.

"The key to success for a clinical trial often rests in identifying the right patients to enroll or in identifying biomarkers for efficacy/safety as early as possible in development. To that end, we're excited to partner with G3 and gain access to both their deep domain expertise and robust panomic datasets to support the development strategies of our biopharmaceutical clients," said Travis May, President and Co-Founder of Datavant.

About G3G3 is the leading precision-medicine-based biopharmaceutical company, developing genetically validated drug targets and novel biomarkers based on biological Big Data, using novel artificial intelligence and machine-learning algorithms and traditional systems-biology-driven bioinformatics approaches to unravel new biologies of common, chronic diseases and rare diseases. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and systems-biology driven bioinformatics to investigate the development and progression of common chronic diseases, as well as rare and orphan diseases.

For additional information, please visit

About DatavantDatavant is a San Francisco-based company dedicated to organizing the world's healthcare data. Datavant's products improve the design and interpretation of clinical trials through data integration and artificial intelligence, increasing the odds of success for clinical trials and helping more drugs reach patients.

Datavant's vision is backed by Roivant Sciences, SoftBank Vision Fund, and Founders Fund.


G3 Contact:Brad Brown; VP of Clinical

Datavant Contact:Sam Roosz; Head of Business Development &

Cision View original content:

SOURCE Datavant


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store